Sanofi-Aventis and Bristol-Myers Squibb announced that they'd nabbed FDA approval for a new 300 mg strength of the anti-clotting drug Plavix, for use as a loading dose when heart patients come into the ER. Release
Sanofi-Aventis and Bristol-Myers Squibb announced that they'd nabbed FDA approval for a new 300 mg strength of the anti-clotting drug Plavix, for use as a loading dose when heart patients come into the ER. Release